KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 48.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,106 shares of the specialty pharmaceutical company's stock after acquiring an additional 36,279 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.22% of KalVista Pharmaceuticals worth $1,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the business. Aquatic Capital Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at $44,000. GAMMA Investing LLC boosted its stake in shares of KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after buying an additional 3,767 shares during the period. Tower Research Capital LLC TRC lifted its stake in KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 5,502 shares during the last quarter. Legal & General Group Plc grew its stake in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares in the last quarter. Finally, Martin Worley Group acquired a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth about $86,000.

Analysts Set New Price Targets

Several equities analysts have issued reports on KALV shares. Jones Trading restated a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock traded down $0.55 during trading hours on Tuesday, reaching $14.21. 644,134 shares of the stock were exchanged, compared to its average volume of 438,313. The stock has a market cap of $706.46 million, a P/E ratio of -3.90 and a beta of -0.01. The firm's 50 day moving average is $12.21 and its 200 day moving average is $10.68. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,169 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $14.50, for a total value of $103,950.50. Following the completion of the transaction, the chief executive officer now directly owns 315,074 shares in the company, valued at approximately $4,568,573. This represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was acquired at an average cost of $9.42 per share, for a total transaction of $235,500.00. Following the completion of the purchase, the insider now owns 5,303,985 shares in the company, valued at $49,963,538.70. The trade was a 0.47% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 15,899 shares of company stock worth $206,176. 10.50% of the stock is owned by insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).